Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

967
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
967
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

783
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
783
Drugs Affecting GI Tract Motility: Other Laxatives01:20

Drugs Affecting GI Tract Motility: Other Laxatives

1.2K
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
1.2K
Neural Regulation01:37

Neural Regulation

43.6K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Associations of daily step counts with cognitive, clinical, and resting-state electroencephalographic measures in patients with cognitive decline due to Alzheimer's disease.

GeroScience·2026
Same author

Glymphatic clearance as revealed by diffusion tensor imaging along the perivascular space (DTI-ALPS) is associated with Alzheimer's disease neuropathology and periodic rsEEG alpha rhythms in mild cognitive impairment participants.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson's disease on stable symptomatic monotherapy (PADOVA): a phase 2b, multicentre, randomised, double-blind, placebo-controlled study.

Lancet (London, England)·2026
Same author

Abnormal periodic and aperiodic resting-state electroencephalographic markers in Lewy body and Alzheimer's diseases with cognitive decline.

GeroScience·2026
Same author

Long-term follow up of opicapone as add-on to levodopa in Parkinson's patients without motor fluctuations.

Journal of Parkinson's disease·2026
Same author

Gender differences in non-motor symptoms in Parkinson's disease: a multicenter longitudinal study.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2026
Same journal

Glutamate-Glutamine metabolism and transport, implications in Parkinson's disease.

International review of neurobiology·2026
Same journal

Redox bioenergetics of neuronal senescence in Alzheimer's disease.

International review of neurobiology·2026
Same journal

Neurovascular coupling and energy substrate delivery in Alzheimer's disease.

International review of neurobiology·2026
Same journal

From metals to mitochondria: Linking trace elements to energy crisis in Alzheimer's disease.

International review of neurobiology·2026
Same journal

Invisible threats of microplastics induced toxicity: Oxidative and inflammatory pathways in the CNS and retina.

International review of neurobiology·2026
Same journal

Starved synapses: Gut microbiome dysbiosis and its role in Alzheimer's glucose impairment.

International review of neurobiology·2026
See all related articles

Related Experiment Video

Updated: Feb 24, 2026

Author Spotlight: Exploring Non-Motor Symptoms in Parkinson's Disease
03:20

Author Spotlight: Exploring Non-Motor Symptoms in Parkinson's Disease

Published on: September 22, 2023

2.4K

Constipation in Parkinson's Disease.

Fabrizio Stocchi1, Margherita Torti1

  • 1University and Institute for Research and Medical Care, IRCCS San Raffaele, Rome, Italy.

International Review of Neurobiology
|August 15, 2017
PubMed
Summary
This summary is machine-generated.

Constipation is a common non-motor symptom in Parkinson's disease (PD) and may precede motor symptoms, indicating early nervous system involvement. Effective management of constipation is crucial for PD patients to prevent complications and improve levodopa treatment response.

Keywords:
ConstipationEnteric nervous systemNonmotor symptomsPD risk factorsParkinson's diseasePuborectalis dyssynergia

More Related Videos

Assessing Gastrointestinal Motility in Caenorhabditis elegans RAC1/CED-10 Mutants as a Tool to Study Early Parkinson's Disease
05:17

Assessing Gastrointestinal Motility in Caenorhabditis elegans RAC1/CED-10 Mutants as a Tool to Study Early Parkinson's Disease

Published on: November 28, 2025

330
Acupoint Application Combined with Acupoint Massage for Treating Constipation in a Patient with Chronic Obstructive Pulmonary Disease
03:50

Acupoint Application Combined with Acupoint Massage for Treating Constipation in a Patient with Chronic Obstructive Pulmonary Disease

Published on: August 18, 2023

3.0K

Related Experiment Videos

Last Updated: Feb 24, 2026

Author Spotlight: Exploring Non-Motor Symptoms in Parkinson's Disease
03:20

Author Spotlight: Exploring Non-Motor Symptoms in Parkinson's Disease

Published on: September 22, 2023

2.4K
Assessing Gastrointestinal Motility in Caenorhabditis elegans RAC1/CED-10 Mutants as a Tool to Study Early Parkinson's Disease
05:17

Assessing Gastrointestinal Motility in Caenorhabditis elegans RAC1/CED-10 Mutants as a Tool to Study Early Parkinson's Disease

Published on: November 28, 2025

330
Acupoint Application Combined with Acupoint Massage for Treating Constipation in a Patient with Chronic Obstructive Pulmonary Disease
03:50

Acupoint Application Combined with Acupoint Massage for Treating Constipation in a Patient with Chronic Obstructive Pulmonary Disease

Published on: August 18, 2023

3.0K

Area of Science:

  • Neurology
  • Gastroenterology

Background:

  • Constipation is a prevalent and disabling non-motor symptom in Parkinson's disease (PD), affecting 24.6% to 63% of patients.
  • Constipation is recognized as a risk factor for PD and may precede motor symptom onset, suggesting early enteric nervous system and dorsal motor nucleus of the vagus involvement in alpha-synuclein pathology.

Purpose of the Study:

  • To highlight the significance of constipation as an early indicator and risk factor in Parkinson's disease.
  • To emphasize the importance of diagnosing and treating constipation in PD patients.

Main Methods:

  • Review of existing literature on constipation in Parkinson's disease.
  • Analysis of the relationship between constipation, PD risk, and alpha-synuclein pathology.
  • Consideration of contributing factors like medications and physiological mechanisms (colonic transit, dyssynergia).

Main Results:

  • Constipation's high prevalence and its role as a potential prodromal symptom in PD.
  • Evidence linking constipation severity and frequency to PD risk.
  • Identification of slower colonic transit and puborectalis dyssynergia as primary causes in PD, exacerbated by medications.

Conclusions:

  • Accurate diagnosis and treatment of constipation are essential for PD management.
  • Addressing constipation can prevent complications like intestinal occlusion.
  • Optimizing constipation management may improve the clinical response to levodopa therapy in Parkinson's disease patients.